GlassScriptPhysician profile
Teandrea Lynette Mcdaniel
NPI 1598494734
$4,053.54
in general payments reported to CMS, 2019-2025
29 companies · $666 in 2025
The $666 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $1,739 · 2024: $1,427 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,831.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $565.61 | 2022-2025 | Caplyta |
| Abbvie INC. | $529.22 | 2022-2025 | |
| Novo Nordisk INC | $486.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $456.02 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Supernus Pharmaceuticals, INC. | $403.09 | 2023-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $267.05 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Lilly USA, LLC | $229.90 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $209.16 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $111.44 | 2023-2025 | |
| Lundbeck LLC | $103.94 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $102.25 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $87.51 | 2022-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Uswm, LLC | $75.56 | 2023 | Lucemyra |
| Neurocrine Biosciences, INC. | $63.51 | 2023-2025 | Ingrezza |
| Pfizer INC. | $59.53 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $52.14 | 2025 | Minimed 780g |
| Astellas Pharma US INC | $41.26 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $21.95 | 2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $20.12 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $19.92 | 2023 | Aptima |
| Indivior INC. | $18.90 | 2023 | Sublocade |
| Tempus Ai, INC | $18.45 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $18.08 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.39 | 2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $15.97 | 2025 | Zenpep |
| Abiomed | $15.78 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.60 | 2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.60 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teandrea Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.